4 datasets found
  1. c

    National Lung Screening Trial

    • cancerimagingarchive.net
    • dev.cancerimagingarchive.net
    dicom, docx, n/a +2
    Updated Sep 24, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    The Cancer Imaging Archive (2021). National Lung Screening Trial [Dataset]. http://doi.org/10.7937/TCIA.HMQ8-J677
    Explore at:
    docx, svs, dicom, n/a, sas, zip, and docAvailable download formats
    Dataset updated
    Sep 24, 2021
    Dataset authored and provided by
    The Cancer Imaging Archive
    License

    https://www.cancerimagingarchive.net/data-usage-policies-and-restrictions/https://www.cancerimagingarchive.net/data-usage-policies-and-restrictions/

    Time period covered
    Sep 24, 2021
    Dataset funded by
    National Cancer Institutehttp://www.cancer.gov/
    Description

    https://www.cancerimagingarchive.net/wp-content/uploads/nctn-logo-300x108.png" alt="" width="300" height="108" />

    Demographic Summary of Available Imaging

    CharacteristicValue (N = 26254)
    Age (years)Mean ± SD: 61.4± 5
    Median (IQR): 60 (57-65)
    Range: 43-75
    SexMale: 15512 (59%)
    Female: 10742 (41%)
    Race

    White: 23969 (91.3%)
    Black: 1135 (4.3%)
    Asian: 547 (2.1%)
    American Indian/Alaska Native: 88 (0.3%)
    Native Hawaiian/Other Pacific Islander: 87 (0.3%)
    Unknown: 428 (1.6%)

    Ethnicity

    Not Available

    Background: The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer.

    Methods: From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. This dataset includes the low-dose CT scans from 26,254 of these subjects, as well as digitized histopathology images from 451 subjects.

    Results: The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02).

    Conclusions: Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385).

    Data Availability: A summary of the National Lung Screening Trial and its available datasets are provided on the Cancer Data Access System (CDAS). CDAS is maintained by Information Management System (IMS), contracted by the National Cancer Institute (NCI) as keepers and statistical analyzers of the NLST trial data. The full clinical data set from NLST is available through CDAS. Users of TCIA can download without restriction a publicly distributable subset of that clinical data, along with the CT and Histopathology images collected during the trial. (These previously were restricted.)

  2. d

    COVID-19 Cases and Deaths by Race/Ethnicity - ARCHIVE

    • catalog.data.gov
    • data.ct.gov
    • +1more
    Updated Aug 12, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    data.ct.gov (2023). COVID-19 Cases and Deaths by Race/Ethnicity - ARCHIVE [Dataset]. https://catalog.data.gov/dataset/covid-19-cases-and-deaths-by-race-ethnicity
    Explore at:
    Dataset updated
    Aug 12, 2023
    Dataset provided by
    data.ct.gov
    Description

    Note: DPH is updating and streamlining the COVID-19 cases, deaths, and testing data. As of 6/27/2022, the data will be published in four tables instead of twelve. The COVID-19 Cases, Deaths, and Tests by Day dataset contains cases and test data by date of sample submission. The death data are by date of death. This dataset is updated daily and contains information back to the beginning of the pandemic. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Cases-Deaths-and-Tests-by-Day/g9vi-2ahj. The COVID-19 State Metrics dataset contains over 93 columns of data. This dataset is updated daily and currently contains information starting June 21, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-State-Level-Data/qmgw-5kp6 . The COVID-19 County Metrics dataset contains 25 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-County-Level-Data/ujiq-dy22 . The COVID-19 Town Metrics dataset contains 16 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Town-Level-Data/icxw-cada . To protect confidentiality, if a town has fewer than 5 cases or positive NAAT tests over the past 7 days, those data will be suppressed. COVID-19 cases and associated deaths that have been reported among Connecticut residents, broken down by race and ethnicity. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Deaths reported to the either the Office of the Chief Medical Examiner (OCME) or Department of Public Health (DPH) are included in the COVID-19 update. The following data show the number of COVID-19 cases and associated deaths per 100,000 population by race and ethnicity. Crude rates represent the total cases or deaths per 100,000 people. Age-adjusted rates consider the age of the person at diagnosis or death when estimating the rate and use a standardized population to provide a fair comparison between population groups with different age distributions. Age-adjustment is important in Connecticut as the median age of among the non-Hispanic white population is 47 years, whereas it is 34 years among non-Hispanic blacks, and 29 years among Hispanics. Because most non-Hispanic white residents who died were over 75 years of age, the age-adjusted rates are lower than the unadjusted rates. In contrast, Hispanic residents who died tend to be younger than 75 years of age which results in higher age-adjusted rates. The population data used to calculate rates is based on the CT DPH population statistics for 2019, which is available online here: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Population-Statistics. Prior to 5/10/2021, the population estimates from 2018 were used. Rates are standardized to the 2000 US Millions Standard population (data available here: https://seer.cancer.gov/stdpopulations/). Standardization was done using 19 age groups (0, 1-4, 5-9, 10-14, ..., 80-84, 85 years and older). More information about direct standardization for age adjustment is available here: https://www.cdc.gov/nchs/data/statnt/statnt06rv.pdf Categories are mutually exclusive. The category “multiracial” includes people who answered ‘yes’ to more than one race category. Counts may not add up to total case counts as data on race and ethnicity may be missing. Age adjusted rates calculated only for groups with more than 20 deaths. Abbreviation: NH=Non-Hispanic. Data on Connecticut deaths were obtained from the Connecticut Deaths Registry maintained by the DPH Office of Vital Records. Cause of death was determined by a death certifier (e.g., physician, APRN, medical

  3. f

    Cohort characteristics and incidence rates.

    • plos.figshare.com
    • figshare.com
    xls
    Updated Jun 23, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Robert J. Huang; Vidhya Balasubramanian; Miranda V. Shum; Hanlee P. Ji; Joo Ha Hwang (2025). Cohort characteristics and incidence rates. [Dataset]. http://doi.org/10.1371/journal.pone.0315833.t001
    Explore at:
    xlsAvailable download formats
    Dataset updated
    Jun 23, 2025
    Dataset provided by
    PLOS ONE
    Authors
    Robert J. Huang; Vidhya Balasubramanian; Miranda V. Shum; Hanlee P. Ji; Joo Ha Hwang
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    BackgroundChronic atrophic gastritis (CAG) is a precancerous condition of the gastric mucosa which predisposes to non-cardia gastric cancer (NCGC). The risk for NCGC following diagnosis with CAG has not been described robustly in the United States.MethodsWe used a commercial claims database (Marketscan, Merative LP) covering over 150 million privately-insured Americans aged 18–64 to create a cohort of individuals diagnosed with CAG. We then followed these individuals for the development of NCGC or to the time of their last clinical encounter. Demographic and clinical characteristics were captured through administrative coding schema, and linked to metropolitan statistical area measures of socioeconomic status. Individual race and ethnicity were not available for this analysis.FindingsWe analyzed data on 107,835 individuals and recorded 355,591 person-years (p-y) of follow-up. The crude overall incidence of NCGC was 98 per 100,000 p-y. In the fully-adjusted multivariable proportional hazards model, age ≥ 50 (HR 2.20, 95% CI 1.44–3.36), anemia (HR 5.09, 95% CI 3.46–7.50), former or current smoking (HR 1.42, 95% CI 1.11–1.81) and family history (HR 1.44, 95% CI 1.05–1.99) were individual-level factors associated with increased risk.ConclusionsWe present one of the first estimates of NCGC risk following CAG diagnosis in an American population, and highlight risk factors for cancer progression. These data may help to guide future risk prevention strategies, such as endoscopic surveillance, in the United States.

  4. Trends in lung and bronchus cancer incidence rates in the United States SEER...

    • plos.figshare.com
    xls
    Updated Jun 1, 2023
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Rafael Meza; Clare Meernik; Jihyoun Jeon; Michele L. Cote (2023). Trends in lung and bronchus cancer incidence rates in the United States SEER 9 registry in males by race and histology, 1973–2010. [Dataset]. http://doi.org/10.1371/journal.pone.0121323.t001
    Explore at:
    xlsAvailable download formats
    Dataset updated
    Jun 1, 2023
    Dataset provided by
    PLOShttp://plos.org/
    Authors
    Rafael Meza; Clare Meernik; Jihyoun Jeon; Michele L. Cote
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Area covered
    United States
    Description

    *Annual percent change (APC) is significantly different from zero at α = 0.05.APC based on incidence rates per 100,000 person-years.AC, adenocarcinoma, BAC, bronchioloalveolar.Trends in lung and bronchus cancer incidence rates in the United States SEER 9 registry in males by race and histology, 1973–2010.

  5. Not seeing a result you expected?
    Learn how you can add new datasets to our index.

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
The Cancer Imaging Archive (2021). National Lung Screening Trial [Dataset]. http://doi.org/10.7937/TCIA.HMQ8-J677

National Lung Screening Trial

NLST

Explore at:
27 scholarly articles cite this dataset (View in Google Scholar)
docx, svs, dicom, n/a, sas, zip, and docAvailable download formats
Dataset updated
Sep 24, 2021
Dataset authored and provided by
The Cancer Imaging Archive
License

https://www.cancerimagingarchive.net/data-usage-policies-and-restrictions/https://www.cancerimagingarchive.net/data-usage-policies-and-restrictions/

Time period covered
Sep 24, 2021
Dataset funded by
National Cancer Institutehttp://www.cancer.gov/
Description

https://www.cancerimagingarchive.net/wp-content/uploads/nctn-logo-300x108.png" alt="" width="300" height="108" />

Demographic Summary of Available Imaging

CharacteristicValue (N = 26254)
Age (years)Mean ± SD: 61.4± 5
Median (IQR): 60 (57-65)
Range: 43-75
SexMale: 15512 (59%)
Female: 10742 (41%)
Race

White: 23969 (91.3%)
Black: 1135 (4.3%)
Asian: 547 (2.1%)
American Indian/Alaska Native: 88 (0.3%)
Native Hawaiian/Other Pacific Islander: 87 (0.3%)
Unknown: 428 (1.6%)

Ethnicity

Not Available

Background: The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer.

Methods: From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. This dataset includes the low-dose CT scans from 26,254 of these subjects, as well as digitized histopathology images from 451 subjects.

Results: The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02).

Conclusions: Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385).

Data Availability: A summary of the National Lung Screening Trial and its available datasets are provided on the Cancer Data Access System (CDAS). CDAS is maintained by Information Management System (IMS), contracted by the National Cancer Institute (NCI) as keepers and statistical analyzers of the NLST trial data. The full clinical data set from NLST is available through CDAS. Users of TCIA can download without restriction a publicly distributable subset of that clinical data, along with the CT and Histopathology images collected during the trial. (These previously were restricted.)

Search
Clear search
Close search
Google apps
Main menu